Clinical Trial Search

Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707

Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Age at Baseline — 70 years

Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants

Primary: Median Overall Survival — 13.9 months

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Objective Response Rate — 56.4 percentage of participants

Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants

Primary: Overall Objective Response — 3; 29; 39 participants

Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants

Primary: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days — 63 percentage of participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Overall Response Rate — 2; 11; 2 Participants

Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients

Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants

Primary: Percentage of Participants With Adverse Events (AEs) — 900 Participants

Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants

Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score. — -2; -3 score on a scale

Primary: Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue, as Measured by Immunohistochemistry After the Completion of Treatment — 52.63; 83.33; 93.33…

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772

Primary: Percentage of Participants That Respond to Treatment in Arm 1 and Arm 2 — 57.1; 61.4 percentage of participants

Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS

Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants

Primary: Objective Response Rate (ORR) — 1; 2 Participants

Primary: Tumor Response Rate — 4.5 percentage of responders